Cancer, CNS & Cardiovascular Biomarkers · Cancer, CNS & Cardiovascular Biomarkers: Players,...
Transcript of Cancer, CNS & Cardiovascular Biomarkers · Cancer, CNS & Cardiovascular Biomarkers: Players,...
World Leaders in Health Industry Analysis
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
©Espicom Business Intelligence August 2008ii
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
August 2008
ISBN: 978-1-85822-327-8
© Copyright 2008 Espicom Business Intelligence
All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of
the publisher.
Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.
British Library Cataloguing in Publication Data.
A catalogue record for this report is available from the British Library.
©Espicom Business Intelligence iiiAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Table of Contents
ContentsEXECUTIVE SUMMARY .................................................................................................................................. 1
Figure1: Growth in biomarker market 2007-2015 .................................................................................................................................................................................1What are biomarkers? ...........................................................................................................................................................2Why are they important? ......................................................................................................................................................2
Figure 2: Potential impact of biomarkers on disease pathways ............................................................................................................................................................2What technologies are involved? .........................................................................................................................................3What impact will biomarkers have on R&D? .......................................................................................................................3
Figure 3: Potential impact of biomarkers on R&D ..................................................................................................................................................................................3Who are the major biomarker players and in what research area? ..................................................................................4Cancer biomarker companies ..............................................................................................................................................5Cardiovascular biomarker companies .................................................................................................................................6CNS biomarkers companies ..................................................................................................................................................7Company Analysis Criteria ....................................................................................................................................................7
Biomarker technology & platforms ................................................................................................................................................7Association/clinical studies ..............................................................................................................................................................8Management strategy ......................................................................................................................................................................8Application & potential .....................................................................................................................................................................8
CANCER MARKET & REVENUES .................................................................................................................... 9Market revenues - global ......................................................................................................................................................9
Figure 1: Global cancer drugs sales (2007) .............................................................................................................................................................................................9Market revenues – leading brands ....................................................................................................................................10
Figure 2: Leading cancer brands (2007) ...............................................................................................................................................................................................10Market revenues – leading players ....................................................................................................................................11
Figure 3: Top 10 oncology players (2007 revenues) .............................................................................................................................................................................11CANCER EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT ................................................................................ 12
Epidemiology .......................................................................................................................................................................12Table 1: Cancer Statistics for four most common cancers, 2008 ..........................................................................................................................................................12
Diagnosis ..............................................................................................................................................................................12Screening .............................................................................................................................................................................13
Table 2: Cancer screening .....................................................................................................................................................................................................................13Current & future treatment ................................................................................................................................................14Future treatment .................................................................................................................................................................14
Figure 4: Anticancer drugs in clinical development..............................................................................................................................................................................15CANCER BIOMARKERS ........................................................................................................................................................... 16
Cancer biomarker R&D ........................................................................................................................................................16Table 3: Types of biomarker ..................................................................................................................................................................................................................17
Known cancer biomarkers ..................................................................................................................................................17Table 4: Commercially available known cancer biomarker diagnostics ..............................................................................................................................................17
Probable and possible valid cancer biomarkers ..............................................................................................................18Table 5: Probable cancer biomarkers diagnostics ................................................................................................................................................................................19Table 6: Possible cancer biomarkers diagnostics ..................................................................................................................................................................................19
CANCER BIOMARKER OPPORTUNITIES & CHALLENGES ................................................................................................... 21Opportunities ......................................................................................................................................................................21Challenges ............................................................................................................................................................................21
BIOMARKER MARKET .............................................................................................................................................................23Biomarker market revenues - global ................................................................................................................................ 23
Figure 8: Global biomarker sales in 2007 .............................................................................................................................................................................................23Cancer biomarker market revenues - global ................................................................................................................... 24
Figure 9: Global cancer biomarker sales in 2007 .................................................................................................................................................................................24
©Espicom Business Intelligence August 2008iv
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Future biomarker market revenues – global ................................................................................................................... 24Figure 10: Global biomarker sales in 2015 ...........................................................................................................................................................................................25
Future cancer biomarker market revenues - global ........................................................................................................ 25Figure 11: Global cancer biomarker sales in 2015 ................................................................................................................................................................................26
CANCER BIOMARKER TRENDS .............................................................................................................................................. 27Table 7: Recent deals in oncology biomarkers ......................................................................................................................................................................................27
Pharma and specialty pharma deals ................................................................................................................................ 29Collaborations with service providers ............................................................................................................................. 29Collaborations with academics and consortia ................................................................................................................ 29
BIOMARKER ANALYSIS ...........................................................................................................................................................30DNA biomarkers ................................................................................................................................................................. 30RNA and microRNA biomarkers ........................................................................................................................................ 30Proteomic biomarkers ....................................................................................................................................................... 30
KEY BIOMARKER COMPANIES ANALYSED ........................................................................................................................... 31KEY BIOMARKER EVALUATION CRITERIA ............................................................................................................................ 32
CANCER BIOMARKER- COMPANY ANALYSIS ............................................................................................. 33Abbott Diagnostics ................................................................................................................................................................. 33
Biomarker novelty & technology platform .......................................................................................................................33Figure 12: Abbott’s UroVysion bladder cancer test ...............................................................................................................................................................................33
Association studies/clinical data ....................................................................................................................................... 34Pivotal Trial ........................................................................................................................................................................................34Table 7: Comparison of UroVysion vs Cystoscopy/Histology for Detection of Bladder Cancer Recurrence by Stage and Grade* .........................................................34
Management strategy ....................................................................................................................................................... 34Application & market potential ........................................................................................................................................ 34Biomarker analysis ..............................................................................................................................................................35
Affymetrix ................................................................................................................................................................................ 36Biomarker novelty & technology platform ...................................................................................................................... 36
Figure 13: Affymetrix’ approach to biomarker discovery, validation and clinical utility applications .................................................................................................36Association studies/clinical data ........................................................................................................................................37Management strategy ........................................................................................................................................................37Application & market potential .........................................................................................................................................37Biomarker analysis ..............................................................................................................................................................37
Agendia BV............................................................................................................................................................................... 39Biomarker novelty & technology platform ...................................................................................................................... 39Association studies/clinical data ....................................................................................................................................... 39
Figure 14: MammaPrint Profile vs NIH Consensus Criteria ...................................................................................................................................................................39Management strategy ....................................................................................................................................................... 40Application & market potential ........................................................................................................................................ 40Biomarker analysis ............................................................................................................................................................. 40
AltheaDx ................................................................................................................................................................................... 41Biomarker novelty & technology platform .......................................................................................................................41Association studies/clinical data ........................................................................................................................................41Management strategy ........................................................................................................................................................41Application & market potential .........................................................................................................................................41Biomarker analysis ..............................................................................................................................................................41
AVEO Pharmaceuticals ........................................................................................................................................................... 43Biomarker novelty & technology platform ...................................................................................................................... 43Association studies/clinical data ....................................................................................................................................... 43Management strategy ....................................................................................................................................................... 43Application & market potential ........................................................................................................................................ 43Biomarker analysis ............................................................................................................................................................. 44
©Espicom Business Intelligence vAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
AviaraDx ................................................................................................................................................................................... 45Biomarker novelty & technology platform ...................................................................................................................... 45Association studies/clinical data ....................................................................................................................................... 45Management strategy ....................................................................................................................................................... 45Application & market potential ........................................................................................................................................ 46Biomarker analysis ............................................................................................................................................................. 46
BG Medicine ............................................................................................................................................................................. 47Biomarker novelty & technology platform .......................................................................................................................47Association studies/clinical data ........................................................................................................................................47Management strategy ........................................................................................................................................................47
Figure 15: BG Medicines Biomarker Programme .................................................................................................................................................................................48Application & market potential ........................................................................................................................................ 48Biomarker analysis ............................................................................................................................................................. 48
Beckman Coulter ....................................................................................................................................................................50Biomarker novelty & technology platform ...................................................................................................................... 50Association studies/clinical data ....................................................................................................................................... 50Management strategy ....................................................................................................................................................... 50Application & market potential .........................................................................................................................................51Biomarker analysis ..............................................................................................................................................................51
BioCurex ................................................................................................................................................................................... 52Biomarker novelty & technology platform .......................................................................................................................52Association studies/clinical data ........................................................................................................................................52Management strategy ........................................................................................................................................................52Application & market potential .........................................................................................................................................53Biomarker analysis ..............................................................................................................................................................53
Biomedical Diagnostics .........................................................................................................................................................54Biomarker novelty & technology platform ...................................................................................................................... 54Association studies/clinical data ....................................................................................................................................... 54Management strategy ....................................................................................................................................................... 54Application & market potential ........................................................................................................................................ 54Biomarker analysis ..............................................................................................................................................................55
Biomerica .................................................................................................................................................................................56Biomarker novelty & technology platform ...................................................................................................................... 56Association studies/clinical data ....................................................................................................................................... 56Management strategy ....................................................................................................................................................... 56Application & market potential ........................................................................................................................................ 56Biomarker analysis ..............................................................................................................................................................57
Bruker Daltonics ......................................................................................................................................................................58Biomarker novelty & technology platform ...................................................................................................................... 58Association studies/clinical data ....................................................................................................................................... 58Management strategy ....................................................................................................................................................... 58Application & market potential ........................................................................................................................................ 58Biomarker analysis ............................................................................................................................................................. 58
Caprion Proteomics ................................................................................................................................................................60Biomarker novelty & technology platform ...................................................................................................................... 60Association studies/clinical data ....................................................................................................................................... 60Management strategy ....................................................................................................................................................... 60Application & market potential ........................................................................................................................................ 60Biomarker analysis ............................................................................................................................................................. 60
Clinical Data ............................................................................................................................................................................. 62Biomarker novelty & technology platform ...................................................................................................................... 62
©Espicom Business Intelligence August 2008vi
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Association studies/clinical data ....................................................................................................................................... 62Management strategy ....................................................................................................................................................... 62Application & market potential ........................................................................................................................................ 62Biomarker analysis ............................................................................................................................................................. 63
Celera ........................................................................................................................................................................................64Biomarker novelty & technology platform ...................................................................................................................... 64Association studies/clinical data ....................................................................................................................................... 64Management strategy ....................................................................................................................................................... 64Application & market potential ........................................................................................................................................ 65Biomarker analysis ............................................................................................................................................................. 65
Dako Denmark A/S .................................................................................................................................................................66Biomarker novelty & technology platform ...................................................................................................................... 66Association studies/clinical data ....................................................................................................................................... 66Management strategy ....................................................................................................................................................... 66Application & market potential ........................................................................................................................................ 66Biomarker analysis ..............................................................................................................................................................67
DxS Ltd ......................................................................................................................................................................................68Biomarker novelty & technology platform ...................................................................................................................... 68Association studies/clinical data ....................................................................................................................................... 68Management strategy ....................................................................................................................................................... 68Application & market potential ........................................................................................................................................ 68Biomarker analysis ............................................................................................................................................................. 69
Epigenomics AG ...................................................................................................................................................................... 70Biomarker novelty & technology platform .......................................................................................................................70Association studies/clinical data ........................................................................................................................................70Management strategy .......................................................................................................................................................70Application & market potential .........................................................................................................................................71Biomarker analysis ..............................................................................................................................................................71
Epistem Plc ............................................................................................................................................................................... 72Biomarker novelty & technology platform ...................................................................................................................... 72
Figure 16: Epistem’s Biomarker Drug Development Programme ........................................................................................................................................................72Association studies/clinical data ....................................................................................................................................... 73Management strategy ....................................................................................................................................................... 73Application & market potential ........................................................................................................................................ 73Biomarker analysis ............................................................................................................................................................. 73
GeneNews ................................................................................................................................................................................ 75Biomarker novelty & technology platform .......................................................................................................................75
Figure 17: GeneNews’ Sentinel Principle ..............................................................................................................................................................................................75Association studies/clinical data ........................................................................................................................................76Management strategy ........................................................................................................................................................76Application & market potential .........................................................................................................................................76Biomarker analysis ..............................................................................................................................................................76
Fujirebio Diagnostics, Inc ...................................................................................................................................................... 78Biomarker novelty & technology platform ...................................................................................................................... 78Association studies/clinical data ....................................................................................................................................... 78Management strategy ....................................................................................................................................................... 78Application & market potential ........................................................................................................................................ 79Biomarker analysis ............................................................................................................................................................. 79
Genomic Health ......................................................................................................................................................................80Biomarker novelty & technology platform ...................................................................................................................... 80
Figure 18: Oncotype Dx test for invasive breast cancer ........................................................................................................................................................................80
©Espicom Business Intelligence viiAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
Association studies/clinical data ....................................................................................................................................... 80Management strategy ........................................................................................................................................................81Application & market potential .........................................................................................................................................81Biomarker analysis ..............................................................................................................................................................81
Gen-Probe ................................................................................................................................................................................ 83Biomarker novelty & technology platform ...................................................................................................................... 83Association studies/clinical data ....................................................................................................................................... 83Management strategy ....................................................................................................................................................... 83Application & market potential ........................................................................................................................................ 84Biomarker analysis ............................................................................................................................................................. 84
Genzyme Genetics ..................................................................................................................................................................85Biomarker novelty & technology platform ...................................................................................................................... 85Association studies/clinical data ....................................................................................................................................... 85Management strategy ....................................................................................................................................................... 85Application & market potential ........................................................................................................................................ 85Biomarker analysis ............................................................................................................................................................. 86
InterGenetics ........................................................................................................................................................................... 87Biomarker novelty & technology platform ...................................................................................................................... 87Association studies/clinical data ....................................................................................................................................... 87Management strategy ....................................................................................................................................................... 87Application & market potential ........................................................................................................................................ 87Biomarker analysis ............................................................................................................................................................. 88
Ipsogen Therapeutics ...........................................................................................................................................................89Biomarker novelty & technology platform ...................................................................................................................... 89Association studies/clinical data ....................................................................................................................................... 89Management strategy ....................................................................................................................................................... 89
Figure 19: Oncotype Dx test for invasive breast cancer ........................................................................................................................................................................90Application & market potential ........................................................................................................................................ 90Biomarker analysis ............................................................................................................................................................. 90
Laboratory Corporation of America .................................................................................................................................... 91Biomarker novelty & technology platform .......................................................................................................................91Association studies/clinical data ........................................................................................................................................91Management strategy ........................................................................................................................................................91Application & market potential .........................................................................................................................................91Biomarker analysis ..............................................................................................................................................................91
Matritech .................................................................................................................................................................................. 93Biomarker novelty & technology platform ...................................................................................................................... 93Association studies/clinical data ....................................................................................................................................... 93Management strategy ....................................................................................................................................................... 93Application & market potential ........................................................................................................................................ 93Biomarker analysis ............................................................................................................................................................. 94
Monogram Biosciences ......................................................................................................................................................... 95Biomarker novelty & technology platform ...................................................................................................................... 95
Figure 20: VeraTag Assay ......................................................................................................................................................................................................................95Association studies/clinical data ....................................................................................................................................... 95
Figure 21: VeraTag Clinical Data: Bordet Cohort ...................................................................................................................................................................................96Management strategy ....................................................................................................................................................... 96Application & market potential ........................................................................................................................................ 96Biomarker analysis ............................................................................................................................................................. 97
Orion Genomics ......................................................................................................................................................................98Biomarker novelty & technology platform ...................................................................................................................... 98
©Espicom Business Intelligence August 2008viii
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Figure 22: Orion’s MethylScope ............................................................................................................................................................................................................98Association studies/clinical data ....................................................................................................................................... 98Management strategy ....................................................................................................................................................... 99Application & market potential ........................................................................................................................................ 99Biomarker analysis ............................................................................................................................................................. 99
Oxford Genome Biosciences (UK) Ltd ...............................................................................................................................100Biomarker novelty & technology platform .................................................................................................................... 100Association studies/clinical data ..................................................................................................................................... 100Management strategy ..................................................................................................................................................... 100Application & market potential ...................................................................................................................................... 100Biomarker analysis ............................................................................................................................................................101
Power3 Medical Products ....................................................................................................................................................102Biomarker novelty & technology platform .................................................................................................................... 102Association studies/clinical data ..................................................................................................................................... 102Management strategy ..................................................................................................................................................... 102
Figure 23: Powder3’s business strategy ..............................................................................................................................................................................................103Application & market potential ...................................................................................................................................... 103Biomarker analysis ........................................................................................................................................................... 103
Predictive Biosciences .......................................................................................................................................................... 105Biomarker novelty & technology platform .................................................................................................................... 105Association studies/clinical data ..................................................................................................................................... 105Management strategy ..................................................................................................................................................... 105Application & market potential ...................................................................................................................................... 105Biomarker analysis ........................................................................................................................................................... 106
Provista Life Sciences ...........................................................................................................................................................107Biomarker novelty & technology platform .................................................................................................................... 107Association studies/clinical data ..................................................................................................................................... 107Management strategy ..................................................................................................................................................... 107Application & market potential ...................................................................................................................................... 108Biomarker analysis ........................................................................................................................................................... 108
Quest Diagnostics .................................................................................................................................................................109Biomarker novelty & technology platform .................................................................................................................... 109Association studies/clinical data ..................................................................................................................................... 109Management strategy ..................................................................................................................................................... 109Application & market potential ...................................................................................................................................... 109Biomarker analysis ............................................................................................................................................................110
Roche Diagnostics .................................................................................................................................................................111Biomarker novelty & technology platform .....................................................................................................................111
Figure 24: Diagnostic marker candidate to a product ........................................................................................................................................................................ 111Association studies/clinical data ......................................................................................................................................112
Figure 25: Biomarkers distinguish Leukaemia subclasses ................................................................................................................................................................. 112Management strategy ......................................................................................................................................................112Application & market potential .......................................................................................................................................113Biomarker analysis ............................................................................................................................................................113
SuperArray Bioscience Corporation .................................................................................................................................. 114Biomarker novelty & technology platform .....................................................................................................................114Association studies/clinical data ......................................................................................................................................114Management strategy ......................................................................................................................................................114Application & market potential .......................................................................................................................................114Biomarker analysis ............................................................................................................................................................114
Third Wave Technologies .................................................................................................................................................... 116
©Espicom Business Intelligence ixAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
Biomarker novelty & technology platform .....................................................................................................................116Association studies/clinical data ......................................................................................................................................116Management strategy ......................................................................................................................................................116Application & market potential .......................................................................................................................................116Biomarker analysis ............................................................................................................................................................117
Upstream Biosciences .......................................................................................................................................................... 118Biomarker novelty & technology platform .....................................................................................................................118Association studies/clinical data ......................................................................................................................................118Management strategy ......................................................................................................................................................118Application & market potential .......................................................................................................................................118Biomarker analysis ............................................................................................................................................................119
Veridex, LLC ........................................................................................................................................................................... 120Biomarker novelty & technology platform .....................................................................................................................120Association studies/clinical data ......................................................................................................................................120Management strategy ......................................................................................................................................................120Application & market potential .......................................................................................................................................121Biomarker analysis ............................................................................................................................................................121
Vermillion ............................................................................................................................................................................... 122Biomarker novelty & technology platform .....................................................................................................................122Association studies/clinical data ......................................................................................................................................122Management strategy ......................................................................................................................................................122Application & market potential .......................................................................................................................................123Biomarker analysis ............................................................................................................................................................123
CANCER BIOMARKER APPENDIX 1 ........................................................................................................... 124Table 8: Global biomarker sales 2007-20015E ...................................................................................................................................................................................124
CANCER BIOMARKER APPENDIX 2 ........................................................................................................... 125Table 8: Global cancer biomarker sales 2007-20015E ........................................................................................................................................................................125
CANCER BIOMARKER APPENDIX 3 ........................................................................................................... 126Company Analysis Criteria .................................................................................................................................................. 126
Biomarker technology & platforms .................................................................................................................................126Association studies ...........................................................................................................................................................126Management strategy .....................................................................................................................................................126Application & potential .....................................................................................................................................................126
Table 9: Key cancer biomarker companies .........................................................................................................................................................................................128Figure 26: Leading Cancer Biomarker Companies – Service providers, Technology Providers, Biomarker Discovery & Diagnostic Developers...............................130
GLOSSARY ..................................................................................................................................................131ACRONYMS ................................................................................................................................................ 133BIBLIOGRAPHY & ENDNOTES ................................................................................................................... 138CNS MARKET & REVENUES ....................................................................................................................... 139
Market revenues - global ..................................................................................................................................................139Figure 1: Global CNS drugs sales (2007) .............................................................................................................................................................................................139
Market revenues – leading brands ................................................................................................................................. 140Figure 2: Leading CNS brands (2007) .................................................................................................................................................................................................140
Market revenues – leading players ..................................................................................................................................141Figure 3: Top 10 CNS players (2007 revenues) ....................................................................................................................................................................................141
CNS EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT ...................................................................................... 142Epidemiology .....................................................................................................................................................................142
Table 1: CNS statistics for the most common CNS disorders, 2008 .....................................................................................................................................................142Diagnosis ............................................................................................................................................................................142
Table 2: Indication for CT and MRI in the CNS .....................................................................................................................................................................................143Screening ...........................................................................................................................................................................143
©Espicom Business Intelligence August 2008x
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Current & future treatment ..............................................................................................................................................143Table 3: Classes of CNS drugs approved for acute and chronic conditions .........................................................................................................................................144
Future treatment .............................................................................................................................................................. 144Figure 4: CNS drugs in clinical development .......................................................................................................................................................................................144
CNS BIOMARKERS ................................................................................................................................................................145CNS biomarker R&D ...........................................................................................................................................................145
Figure 5: Imaging biomarkers as surrogate endpoints ......................................................................................................................................................................146Table 4: Types of biomarker ................................................................................................................................................................................................................146
Known CNS biomarkers ....................................................................................................................................................147Table 5: Commercially available known CNS biomarker diagnostics ................................................................................................................................................147
Probable and possible valid CNS biomarkers .................................................................................................................147Table 6: Probable CNS biomarkers diagnostics .................................................................................................................................................................................148Table 7: Possible CNS biomarkers diagnostics ...................................................................................................................................................................................148
CNS BIOMARKER OPPORTUNITIES & CHALLENGES ........................................................................................................ 152Opportunities ....................................................................................................................................................................152
Figure 7: CNS biomarker opportunities .............................................................................................................................................................................................152Challenges ..........................................................................................................................................................................153
Figure 8: CNS biomarker challenges ..................................................................................................................................................................................................153BIOMARKER MARKET ........................................................................................................................................................... 155
Biomarker market revenues - global ...............................................................................................................................155Figure 9: Global biomarker sales in 2007 ...........................................................................................................................................................................................155
CNS biomarker market revenues - global .......................................................................................................................156Figure 10: Global CNS biomarker sales in 2007 ..................................................................................................................................................................................156
Future biomarker market revenues – global ..................................................................................................................156Figure 11: Global biomarker sales in 2015 ..........................................................................................................................................................................................157
Future CNS biomarker market revenues - global ...........................................................................................................157Figure 12: Global CNS biomarker sales in 2015 ..................................................................................................................................................................................158
CNS BIOMARKER TRENDS .................................................................................................................................................... 159Table 8: Recent deals in the oncology biomarkers .............................................................................................................................................................................159
Pharma deals .................................................................................................................................................................... 160Collaborations with CNS discovery companies ............................................................................................................. 160Collaborations with academics and consortia .............................................................................................................. 160
BIOMARKER ANALYSIS .........................................................................................................................................................162DNA biomarkers ............................................................................................................................................................... 162Proteomic biomarkers ..................................................................................................................................................... 162Metabolomic biomarkers ................................................................................................................................................ 162Electrophysiology biomarkers ........................................................................................................................................ 162Imaging biomarkers ......................................................................................................................................................... 162
KEY BIOMARKER COMPANIES ANALYSED .........................................................................................................................163KEY BIOMARKER EVALUATION CRITERIA ..........................................................................................................................164
CNS BIOMARKER- COMPANY ANALYSIS .................................................................................................. 165Affymetrix ..............................................................................................................................................................................165
Biomarker novelty & technology platform .................................................................................................................... 165Association studies/clinical data ..................................................................................................................................... 165Management strategy ..................................................................................................................................................... 165Application & market potential ...................................................................................................................................... 166Biomarker analysis ........................................................................................................................................................... 166
Applied NeuroSolutions ..................................................................................................................................................... 167Biomarker novelty & technology platform .....................................................................................................................167Association studies/clinical data ......................................................................................................................................167Management strategy ......................................................................................................................................................167
©Espicom Business Intelligence xiAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
Application & market potential .......................................................................................................................................167Biomarker analysis ........................................................................................................................................................... 168
Banyan Biomarkers ..............................................................................................................................................................169Biomarker novelty & technology platform .................................................................................................................... 169
Figure 14: Source Of Banyans TNI biomarkers ...................................................................................................................................................................................169Association studies/clinical data ..................................................................................................................................... 169Management strategy ..................................................................................................................................................... 169Application & market potential ...................................................................................................................................... 169Biomarker analysis ............................................................................................................................................................170
BG Medicine ........................................................................................................................................................................... 171Biomarker novelty & technology platform .....................................................................................................................171Association studies/clinical data ......................................................................................................................................171Management strategy ......................................................................................................................................................171Application & market potential .......................................................................................................................................172Biomarker analysis ............................................................................................................................................................172
Biosite, Inc .............................................................................................................................................................................. 173Biomarker novelty & technology platform .....................................................................................................................173Association studies/clinical data ......................................................................................................................................173Management strategy ......................................................................................................................................................173Application & market potential .......................................................................................................................................174Biomarker analysis ............................................................................................................................................................174
Biospective ............................................................................................................................................................................. 175Biomarker novelty & technology platform .....................................................................................................................175Association studies/clinical data ......................................................................................................................................175Management strategy ......................................................................................................................................................175Application & market potential .......................................................................................................................................175Biomarker analysis ............................................................................................................................................................176
Celera, Inc ............................................................................................................................................................................... 177Biomarker novelty & technology platform .....................................................................................................................177Association studies/clinical data ......................................................................................................................................177Management strategy ......................................................................................................................................................177Application & market potential .......................................................................................................................................177Biomarker analysis ............................................................................................................................................................178
Clinical Data Inc ..................................................................................................................................................................... 179Biomarker novelty & technology platform .....................................................................................................................179Association studies/clinical data ......................................................................................................................................179Management strategy ..................................................................................................................................................... 180Application & market potential ...................................................................................................................................... 180Biomarker analysis ........................................................................................................................................................... 180
Curidium Medica ................................................................................................................................................................... 181Biomarker novelty & technology platform .....................................................................................................................181Association studies/clinical data ......................................................................................................................................181
Figure 17: Curidium’s PsychINDx test for schizophrenia/bipolar disorder ..........................................................................................................................................181Management strategy ..................................................................................................................................................... 182Application & market potential ...................................................................................................................................... 182
Digilab Peptidomics .............................................................................................................................................................183Biomarker novelty & technology platform .................................................................................................................... 183Association studies/clinical data ..................................................................................................................................... 183Management strategy ..................................................................................................................................................... 183Application & market potential ...................................................................................................................................... 183Biomarker analysis ........................................................................................................................................................... 184
©Espicom Business Intelligence August 2008xii
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
EnVivo Pharmaceuticals ......................................................................................................................................................185Biomarker novelty & technology platform .................................................................................................................... 185Association studies/clinical data ..................................................................................................................................... 185Management strategy ..................................................................................................................................................... 185Application & market potential ...................................................................................................................................... 185Biomarker analysis ........................................................................................................................................................... 186
Innogenetics NV ....................................................................................................................................................................187Biomarker novelty & technology platform .................................................................................................................... 187
Figure 18: Innogenetic multiparameter analysis ...............................................................................................................................................................................187Association studies/clinical data ..................................................................................................................................... 187Management strategy ..................................................................................................................................................... 187Application & market potential ...................................................................................................................................... 188Biomarker analysis ........................................................................................................................................................... 188
KineMed, Inc ..........................................................................................................................................................................189Biomarker novelty & technology platform .................................................................................................................... 189
Figure 19: KineMarker technology platform ......................................................................................................................................................................................189Association studies/clinical data ..................................................................................................................................... 190Management strategy ..................................................................................................................................................... 190Application & market potential ...................................................................................................................................... 190Biomarker analysis ........................................................................................................................................................... 190
Lipomics Technologies ........................................................................................................................................................ 191Biomarker novelty & technology platform .....................................................................................................................191Association studies/clinical data ......................................................................................................................................191Management strategy ......................................................................................................................................................191Application & market potential .......................................................................................................................................191Biomarker analysis ............................................................................................................................................................192
Luminex Corporation ........................................................................................................................................................... 193Biomarker novelty & technology platform .....................................................................................................................193Association studies/clinical data ......................................................................................................................................193Management strategy ......................................................................................................................................................193
Figure 20: Luminex is capturing end-user market share ...................................................................................................................................................................194Application & market potential ...................................................................................................................................... 194Biomarker analysis ........................................................................................................................................................... 194
Memory Pharmaceuticals Corporation ............................................................................................................................195Biomarker novelty & technology platform .................................................................................................................... 195Association studies/clinical data ..................................................................................................................................... 195Management strategy ..................................................................................................................................................... 195Application & market potential ...................................................................................................................................... 195Biomarker analysis ........................................................................................................................................................... 196
Metabolon, Inc ...................................................................................................................................................................... 197Biomarker novelty & technology platform .....................................................................................................................197
Figure 21: Metabolon integrated analytic platform ..........................................................................................................................................................................197Association studies/clinical data ......................................................................................................................................197Management strategy ..................................................................................................................................................... 198Application & market potential ...................................................................................................................................... 198Biomarker analysis ........................................................................................................................................................... 198
Nanogen, Inc .........................................................................................................................................................................199Biomarker novelty & technology platform .................................................................................................................... 199Association studies/clinical data ..................................................................................................................................... 199Management strategy ..................................................................................................................................................... 199Application & market potential ...................................................................................................................................... 199
©Espicom Business Intelligence xiiiAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
Biomarker analysis ........................................................................................................................................................... 200Nanosphere, Inc. ...................................................................................................................................................................201
Biomarker novelty & technology platform .................................................................................................................... 201Figure 22. Nanosphere’s gold nanoparticle technology ....................................................................................................................................................................201
Association studies/clinical data ..................................................................................................................................... 202Management strategy ..................................................................................................................................................... 202Application & market potential ...................................................................................................................................... 202Biomarker analysis ........................................................................................................................................................... 202
Nymox Pharmaceutical .......................................................................................................................................................203Biomarker novelty & technology platform .................................................................................................................... 203Association studies/clinical data ..................................................................................................................................... 203Management strategy ..................................................................................................................................................... 203Application & market potential ...................................................................................................................................... 203Biomarker analysis ........................................................................................................................................................... 204
Competitor Ratio Analysis Score = 12/40 ..........................................................................................................................................................................................204Osta Biotechnologies ...........................................................................................................................................................205
Biomarker novelty & technology platform .................................................................................................................... 205Association studies/clinical data ..................................................................................................................................... 205Management strategy ..................................................................................................................................................... 205Application & market potential ...................................................................................................................................... 205Biomarker analysis ........................................................................................................................................................... 206
Phenomenome Discoveries, Inc .........................................................................................................................................207Biomarker novelty & technology platform .................................................................................................................... 207Association studies/clinical data ..................................................................................................................................... 207Management strategy ..................................................................................................................................................... 207Application & market potential ...................................................................................................................................... 207Biomarker analysis ........................................................................................................................................................... 208
PPD, Inc ...................................................................................................................................................................................209Biomarker novelty & technology platform .................................................................................................................... 209Association studies/clinical data ..................................................................................................................................... 209Management strategy ..................................................................................................................................................... 209Application & market potential ...................................................................................................................................... 209Biomarker analysis ............................................................................................................................................................210
Competitor Ratio Analysis Score = 16/40 ..........................................................................................................................................................................................210Power3 Medical Products .................................................................................................................................................... 211
Biomarker novelty & technology platform .....................................................................................................................211Association studies/clinical data ......................................................................................................................................211Management strategy ......................................................................................................................................................211Application & market potential .......................................................................................................................................211Biomarker analysis ............................................................................................................................................................212
Provista Life Sciences ........................................................................................................................................................... 213Biomarker novelty & technology platform .....................................................................................................................213Association studies/clinical data ......................................................................................................................................213Management strategy ......................................................................................................................................................213Application & market potential .......................................................................................................................................213Biomarker analysis ............................................................................................................................................................214
Psynova Neurotech Ltd........................................................................................................................................................ 215Biomarker novelty & technology platform .....................................................................................................................215Association studies/clinical data ......................................................................................................................................215
Figure 23: Two proteins identified in CSF are also biomarkers in serum ............................................................................................................................................ 215Management strategy ......................................................................................................................................................216
©Espicom Business Intelligence August 2008xiv
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Application & market potential .......................................................................................................................................216Biomarker analysis ............................................................................................................................................................216
Satoris, Inc .............................................................................................................................................................................. 217Biomarker novelty & technology platform .....................................................................................................................217Association studies/clinical data ......................................................................................................................................217
Figure 24: Early identification of Alzheimer's disease in at-risk MCI patients ....................................................................................................................................217Management strategy ......................................................................................................................................................218Application & market potential .......................................................................................................................................218Biomarker analysis ............................................................................................................................................................218
Siemens Medical Solutions ................................................................................................................................................. 219Biomarker novelty & technology platform .....................................................................................................................219
Figure 25: Siemens Integrated in vivo & in vitro diagnostic suites .....................................................................................................................................................219Association studies/clinical data ......................................................................................................................................219Management strategy ..................................................................................................................................................... 220Application & market potential ...................................................................................................................................... 220Biomarker analysis ........................................................................................................................................................... 220
Competitor Ratio Analysis Score = 20/40 ..........................................................................................................................................................................................220SuperArray Bioscience Corporation ..................................................................................................................................222
Biomarker novelty & technology platform .................................................................................................................... 222Association studies/clinical data ..................................................................................................................................... 222Management strategy ..................................................................................................................................................... 222Application & market potential ...................................................................................................................................... 222Biomarker analysis ........................................................................................................................................................... 223
CNS BIOMARKER APPENDIX 1 .................................................................................................................. 224Table 9: Global biomarker sales 2007-20015E ...................................................................................................................................................................................224
CNS BIOMARKER APPENDIX 2 .................................................................................................................. 225Table 10: Global CNS biomarker sales 2007-20015E ..........................................................................................................................................................................225
CNS BIOMARKER APPENDIX 3 .................................................................................................................. 226Company Analysis Criteria ..................................................................................................................................................226
Biomarker technology & platforms ................................................................................................................................ 226Association studies .......................................................................................................................................................... 226Management strategy .................................................................................................................................................... 226Application & potential .................................................................................................................................................... 226
Table 9: Key CNS Biomarker Companies .............................................................................................................................................................................................227Figure 26: Leading CNS Biomarker Companies – Service Providers, Technology Providers, Biomarker Discovery & Diagnostic Developers ...................................228
GLOSSARY ................................................................................................................................................. 229ACRONYMS ................................................................................................................................................ 234BIBLIOGRAPHY ......................................................................................................................................... 239CARDIOVASCULAR MARKET & REVENUES .............................................................................................. 241
Market revenues - global ..................................................................................................................................................241Figure 1: Global cardiovascular disease drug sales 2007 ..................................................................................................................................................................241
Market revenues – leading brands ................................................................................................................................. 242Figure 2: Leading Cardiovascular brands (2007) ...............................................................................................................................................................................242
Market revenues – leading players ................................................................................................................................. 243Figure 3: Top 10 cardiovascular players (2007 revenues) ..................................................................................................................................................................243
CARDIOVASCULAR EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT ...........................................................244Epidemiology .................................................................................................................................................................... 244
Figure 4: Breakdown of deaths from cardiovascular diseases in the US (2004) ................................................................................................................................245Diagnosis ........................................................................................................................................................................... 245Screening .......................................................................................................................................................................... 246
Table 1: Screening for cardiovascular disease ....................................................................................................................................................................................246
©Espicom Business Intelligence xvAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
Current treatments .......................................................................................................................................................... 246Table 2: Cardiovascular therapeutic drug categories and their indications .......................................................................................................................................247
Future treatments ............................................................................................................................................................ 247Figure 5: Drugs in clinical development for heart disease ..................................................................................................................................................................248
CARDIOVASCULAR BIOMARKERS ......................................................................................................................................249Cardiovascular biomarker R&D ....................................................................................................................................... 249
Figure 6: Impact of biomarkers on the drug R&D process ..................................................................................................................................................................250Table 3: Types of biomarker ................................................................................................................................................................................................................251
Known cardiovascular biomarkers ................................................................................................................................. 251Table 4: Commercially available cardiovascular diagnostics .............................................................................................................................................................251
Probable and possible valid cardiovascular biomarkers .............................................................................................. 253Table 5: Probable cardiovascular biomarkers ...................................................................................................................................................................................254Table 6: Possible cardiovascular biomarkers .....................................................................................................................................................................................255
CARDIOVASCULAR BIOMARKER OPPORTUNITIES & CHALLENGES ..............................................................................258Opportunities ................................................................................................................................................................... 258
Figure 7: Cardiovascular biomarker opportunities ............................................................................................................................................................................258Challenges ......................................................................................................................................................................... 259
Figure 8: Cardiovascular biomarker challenges ................................................................................................................................................................................259BIOMARKER MARKET ...........................................................................................................................................................261
Biomarker market revenues – global ..............................................................................................................................261Figure 9: Global biomarker sales in 2007 ...........................................................................................................................................................................................261
Cardiovascular biomarker market revenues – global .................................................................................................. 262Figure 10: Global cardiovascular biomarker sales in 2007 ................................................................................................................................................................262
Future biomarker market revenues – global ................................................................................................................. 262Figure 11: Global biomarker sales in 2015 ..........................................................................................................................................................................................263
Future cardiovascular biomarker market revenues – global ....................................................................................... 263Figure 12: Global cardiovascular biomarker sales in 2015 .................................................................................................................................................................263
CARDIOVASCULAR BIOMARKER TRENDS .........................................................................................................................264Table 7: Recent deals in cardiovascular biomarkers ...........................................................................................................................................................................264
Pharma and specialty pharma deals .............................................................................................................................. 265Collaborations with service providers ........................................................................................................................... 265Collaborations with academics and consortia .............................................................................................................. 265
BIOMARKER ANALYSIS .........................................................................................................................................................266Assays for circulating biomarkers ................................................................................................................................... 266DNA and RNA biomarkers ................................................................................................................................................ 266Proteomic, metabolomic biomarkers ............................................................................................................................ 266Systems biology for biomarker discovery ...................................................................................................................... 266Imaging biomarkers ......................................................................................................................................................... 267
KEY BIOMARKER COMPANIES ANALYSED .........................................................................................................................268KEY BIOMARKER EVALUATION CRITERIA ..........................................................................................................................269
CARDIOVASCULAR BIOMARKERS - COMPANY ANALYSIS ....................................................................... 270Abbott Diagnostics ..............................................................................................................................................................270
Biomarker novelty & technology platform .................................................................................................................... 270Association studies/clinical data ..................................................................................................................................... 270Management strategy ..................................................................................................................................................... 270Application & market potential ...................................................................................................................................... 270Biomarker analysis ........................................................................................................................................................... 271
Atherotech .............................................................................................................................................................................272Biomarker novelty & technology platform .................................................................................................................... 272Association studies/clinical data ..................................................................................................................................... 272Management strategy ..................................................................................................................................................... 272
©Espicom Business Intelligence August 2008xvi
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Application & market potential ...................................................................................................................................... 272Biomarker analysis ........................................................................................................................................................... 272
Affymetrix ..............................................................................................................................................................................273Biomarker novelty & technology platform .................................................................................................................... 273
Figure 13: Affymetrix’ approach to biomarker discovery, validation and clinical utility applications ...............................................................................................273Association studies/clinical data ..................................................................................................................................... 273Management strategy ......................................................................................................................................................274Application & market potential .......................................................................................................................................274Biomarker analysis ............................................................................................................................................................275
Beckman Coulter ..................................................................................................................................................................276Biomarker novelty & technology platform .....................................................................................................................276Association studies/clinical data ......................................................................................................................................276Management strategy ......................................................................................................................................................276Application & market potential ...................................................................................................................................... 277Biomarker analysis ........................................................................................................................................................... 277
Berkeley HeartLab ................................................................................................................................................................278Biomarker novelty & technology platform .................................................................................................................... 278
Figure 14: Markers of cardiovascular disease measured at Berkeley HeartLab .................................................................................................................................278Association studies/clinical data ..................................................................................................................................... 278Management strategy ..................................................................................................................................................... 279Application & market potential ...................................................................................................................................... 279Biomarker analysis ........................................................................................................................................................... 279
BG Medicine ..........................................................................................................................................................................280Biomarker novelty & technology platform .................................................................................................................... 280Association studies/clinical data ..................................................................................................................................... 280Management strategy ..................................................................................................................................................... 280
Figure 15: BG Medicine’s Biomarker Programme ..............................................................................................................................................................................281Application & market potential ...................................................................................................................................... 281Biomarker analysis ........................................................................................................................................................... 282
CardioDx .................................................................................................................................................................................283Biomarker novelty & technology platform .................................................................................................................... 283Association studies/clinical data ..................................................................................................................................... 283Management strategy ..................................................................................................................................................... 283Application & market potential ...................................................................................................................................... 283Biomarker analysis ........................................................................................................................................................... 284
Competitor Ratio Analysis Score = 9/40 ............................................................................................................................................................................................284Celera ......................................................................................................................................................................................285
Biomarker novelty & technology platform .................................................................................................................... 285Association studies/clinical data ..................................................................................................................................... 285Management strategy ..................................................................................................................................................... 286Application & market potential ...................................................................................................................................... 286Biomarker analysis ........................................................................................................................................................... 286
CIS Biotech .............................................................................................................................................................................287Biomarker novelty & technology platform .................................................................................................................... 287Association studies/clinical data ..................................................................................................................................... 287Management strategy ..................................................................................................................................................... 287Application & market potential ...................................................................................................................................... 287Biomarker analysis ........................................................................................................................................................... 288
Clinical Data ...........................................................................................................................................................................289Biomarker novelty & technology platform .................................................................................................................... 289Association studies/clinical data ..................................................................................................................................... 289
©Espicom Business Intelligence xviiAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
Management strategy ..................................................................................................................................................... 290Application & market potential ...................................................................................................................................... 290Biomarker analysis ........................................................................................................................................................... 290
Compugen .............................................................................................................................................................................291Biomarker novelty & technology platform .................................................................................................................... 291Association studies/clinical data ..................................................................................................................................... 291Management strategy ..................................................................................................................................................... 291Application & market potential ...................................................................................................................................... 292Biomarker analysis ........................................................................................................................................................... 292
Critical Diagnostics ...............................................................................................................................................................293Biomarker novelty & technology platform .................................................................................................................... 293Association studies/clinical data ..................................................................................................................................... 293Management strategy ..................................................................................................................................................... 293Application & market potential ...................................................................................................................................... 293Biomarker analysis ........................................................................................................................................................... 294
deCODE Genetics ..................................................................................................................................................................295Biomarker novelty & technology platform .................................................................................................................... 295Association studies/clinical data ..................................................................................................................................... 295Management strategy ..................................................................................................................................................... 295
Figure 16: deCODE’s approach to target discovery and development ................................................................................................................................................296Application & market potential ...................................................................................................................................... 296Biomarker analysis ........................................................................................................................................................... 296
diaDexus .................................................................................................................................................................................297Biomarker novelty & technology platform .................................................................................................................... 297Association studies/clinical data ..................................................................................................................................... 297Management strategy ..................................................................................................................................................... 297Application & market potential ...................................................................................................................................... 297Biomarker analysis ........................................................................................................................................................... 298
Entelos ....................................................................................................................................................................................299Biomarker novelty & technology platform .................................................................................................................... 299Association studies/clinical data ..................................................................................................................................... 299Management strategy ..................................................................................................................................................... 299Application & market potential ...................................................................................................................................... 299Biomarker analysis ........................................................................................................................................................... 300
FoxHollow Technologies ....................................................................................................................................................301Biomarker novelty & technology platform .................................................................................................................... 301Association studies/clinical data ..................................................................................................................................... 301Management strategy ..................................................................................................................................................... 301Application & market potential ...................................................................................................................................... 301Biomarker analysis ........................................................................................................................................................... 302
GE Healthcare ........................................................................................................................................................................303Biomarker novelty & technology platform .................................................................................................................... 303
Figure 17: Cardiology focus at GE Healthcare ....................................................................................................................................................................................303Association studies/clinical data ..................................................................................................................................... 304Management strategy ..................................................................................................................................................... 304Application & market potential ...................................................................................................................................... 304Biomarker analysis ........................................................................................................................................................... 304
Genomas ...............................................................................................................................................................................305Biomarker novelty & technology platform .................................................................................................................... 305
Figure 18: PhysioGenomics Technology from Genomas ....................................................................................................................................................................305Association studies/clinical data ..................................................................................................................................... 305
©Espicom Business Intelligence August 2008xviii
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Management strategy ..................................................................................................................................................... 306Application & market potential ...................................................................................................................................... 306Biomarker analysis ........................................................................................................................................................... 306
Inverness Medical Innovations ...........................................................................................................................................307Biomarker novelty & technology platform .................................................................................................................... 307Association studies/clinical data ..................................................................................................................................... 307Management strategy ..................................................................................................................................................... 307Application & market potential ...................................................................................................................................... 308Biomarker analysis ........................................................................................................................................................... 308
Jurilab .....................................................................................................................................................................................309Biomarker novelty & technology platform .................................................................................................................... 309
Figure 19: Jurilab’s Genetic Discovery Method ...................................................................................................................................................................................310Association studies/clinical data ......................................................................................................................................310Management strategy ......................................................................................................................................................311Application & market potential .......................................................................................................................................311Biomarker analysis ............................................................................................................................................................311
Competitor Ratio Analysis Score = 12/40 .......................................................................................................................................................................................... 311Laboratory Corporation of America .................................................................................................................................. 312
Biomarker novelty & technology platform .....................................................................................................................312Association studies/clinical data ......................................................................................................................................312Management strategy ......................................................................................................................................................312Application & market potential .......................................................................................................................................312Biomarker analysis ............................................................................................................................................................313
Lipomics Technologies ........................................................................................................................................................ 314Biomarker novelty & technology platform .....................................................................................................................314Association studies/clinical data ......................................................................................................................................314Management strategy ......................................................................................................................................................314Application & market potential .......................................................................................................................................314Biomarker analysis ............................................................................................................................................................315
LipoScience ............................................................................................................................................................................ 316Biomarker novelty & technology platform .....................................................................................................................316Association studies/clinical data ......................................................................................................................................316Management strategy ......................................................................................................................................................316Application & market potential .......................................................................................................................................316Biomarker analysis ............................................................................................................................................................317
Competitor Ratio Analysis Score = 15/40 .......................................................................................................................................................................................... 317Nanosphere Inc. .................................................................................................................................................................... 318
Biomarker novelty & technology platform .....................................................................................................................318Association studies/clinical data ......................................................................................................................................318Management strategy ......................................................................................................................................................318Application & market potential .......................................................................................................................................318Biomarker analysis ............................................................................................................................................................319
Osmetech Molecular Diagnostics ......................................................................................................................................320Biomarker novelty & technology platform .................................................................................................................... 320Association studies/clinical data ..................................................................................................................................... 320Management strategy ..................................................................................................................................................... 320Application & market potential ...................................................................................................................................... 320Biomarker analysis ............................................................................................................................................................321
Competitor Ratio Analysis Score = 12/40 ..........................................................................................................................................................................................321PrognostiX .............................................................................................................................................................................322
Biomarker novelty & technology platform .................................................................................................................... 322
©Espicom Business Intelligence xixAugust 2008
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name
Association studies/clinical data ..................................................................................................................................... 322Management strategy ..................................................................................................................................................... 322Application & market potential ...................................................................................................................................... 322Biomarker analysis ........................................................................................................................................................... 322
Quest Diagnostics .................................................................................................................................................................323Biomarker novelty & technology platform .................................................................................................................... 323Association studies/clinical data ..................................................................................................................................... 323Management strategy ..................................................................................................................................................... 323Application & market potential ...................................................................................................................................... 323Biomarker analysis ........................................................................................................................................................... 324
Competitor Ratio Analysis Score = 27/40 ..........................................................................................................................................................................................324Roche Diagnostics ................................................................................................................................................................325
Biomarker novelty & technology platform .................................................................................................................... 325Figure 20: Roche’s technologies for biomarker discovery and development .....................................................................................................................................325
Association studies/clinical data ..................................................................................................................................... 325Figure 21: Roche’s clinical trial programme for cardiac biomarker NT-proBNP .................................................................................................................................326
Management strategy ..................................................................................................................................................... 326Application & market potential ...................................................................................................................................... 326Biomarker analysis ........................................................................................................................................................... 327
Siemens Medical Solutions .................................................................................................................................................328Biomarker novelty & technology platform .................................................................................................................... 328
Figure 22: Siemens Integrated in vivo & in vitro diagnostic suites .....................................................................................................................................................328Association studies/clinical data ..................................................................................................................................... 328Management strategy ..................................................................................................................................................... 329Application & market potential ...................................................................................................................................... 329Biomarker analysis ........................................................................................................................................................... 329
Singulex ..................................................................................................................................................................................330Biomarker novelty & technology platform .................................................................................................................... 330
Figure 23: Sensitivity of Singulex’s Erenna system compared to ELISA and bead-based fluorescence readout systems ...................................................................330Association studies/clinical data ..................................................................................................................................... 330Management strategy ......................................................................................................................................................331Application & market potential .......................................................................................................................................331Biomarker analysis ............................................................................................................................................................331
SuperArray Bioscience Corporation ..................................................................................................................................332Biomarker novelty & technology platform .................................................................................................................... 332Association studies/clinical data ..................................................................................................................................... 332Management strategy ..................................................................................................................................................... 332Application & market potential ...................................................................................................................................... 332Biomarker analysis ........................................................................................................................................................... 333
Vermillion ...............................................................................................................................................................................334Biomarker novelty & technology platform .................................................................................................................... 334Association studies/clinical data ..................................................................................................................................... 334Management strategy ..................................................................................................................................................... 334Application & market potential ...................................................................................................................................... 335Biomarker analysis ........................................................................................................................................................... 335
Zora Biosciences OY ..............................................................................................................................................................336Biomarker novelty & technology platform .................................................................................................................... 336
Table 8: Zora metabolite profiling platform .......................................................................................................................................................................................336Association studies/clinical data ..................................................................................................................................... 336Management strategy ..................................................................................................................................................... 336Application & market potential ...................................................................................................................................... 336
©Espicom Business Intelligence August 2008xx
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name
Biomarker analysis ........................................................................................................................................................... 337CARDIOVASCULAR BIOMARKER APPENDIX 1 ......................................................................................... 338
Table 9: Global biomarker sales 2007-20015E ...................................................................................................................................................................................338CARDIOVASCULAR BIOMARKER APPENDIX 2 ......................................................................................... 339
Table 10: Global cardiovascular biomarker sales 2007-20015E .........................................................................................................................................................339CARDIOVASCULAR BIOMARKER APPENDIX 3 ......................................................................................... 340
Company Analysis Criteria ..................................................................................................................................................340Biomarker technology & platforms ................................................................................................................................ 340Association studies .......................................................................................................................................................... 340Management strategy .................................................................................................................................................... 340Application & potential .................................................................................................................................................... 340
Table 9: Key cardiovascular biomarker companies ............................................................................................................................................................................341Figure 26: Leading Cardiovascular Biomarker Companies – Service providers, Technology Providers, Biomarker Discovery & Diagnostic Developers .................343
GLOSSARY ................................................................................................................................................. 344ACRONYMS ................................................................................................................................................ 346BIBLIOGRAPHY & ENDNOTES ................................................................................................................... 350